Enter inventor name

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 9.9

ph-index = 2

Forward Citations = 17(Granted Patents)

Location History:

Taejon-si, KR (2001 - 2008)
Taejeon-si, KR (2007 - 2012)
Daejeon, KR (1993 - 2016)

Company Filing History:

12 out of 624

Korea Research Institute of Chemical Technology

patents

3 out of 12

Dongbu Hannong Chemical Co., Ltd.

Schaeffler Technologies Ag & Co .kg

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195469 - Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof (2025-01-14),

2. 12187729 - Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof (2025-01-07),

3. 9364468 - Pharmaceutical composition for preventing or treating tuberculosis (2016-06-14),

4. 9090608 - Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative (2015-07-28),

5. 8372862 - Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative (2013-02-12),

6. 8198307 - Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same (2012-06-12),

7. 8143307 - Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same (2012-03-27),

8. 7939550 - Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same (2011-05-10),

9. 7420060 - Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them (2008-09-02),

10. 7351843 - Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them (2008-04-01),

11. 7309793 - Benzopyran derivatives substituted with a benzimidazole derivative, pharmaceutically acceptable salts therof, their preparations and pharmaceutical compositions containing them (2007-12-18),

12. 7279497 - Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them (2007-10-09),

13. 6413983 - Benzopyranyl heterocycle derivatives, process for preparation thereof, and pharmaceutical compositions containing them (2002-07-02),

14. 6323238 - Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them (2001-11-27),

15. 5493029 - Certain pyridyl-benzopyran derivatives (1996-02-20),

Title: Kyu Yang Yi: Innovator in PDE9A Inhibitory Compounds

Introduction

Kyu Yang Yi is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with PDE9A inhibitory activity. With a total of 17 patents to his name, Yi's work has the potential to impact the treatment of various diseases.

Latest Patents

One of Yi's latest patents focuses on compounds that exhibit PDE9A inhibitory activity. This invention provides a specific chemical structure that can be utilized in pharmaceutical applications. The patent outlines a composition containing the compound or its pharmaceutically acceptable salt. Furthermore, it details the pharmaceutical use of these compounds for treating or preventing PDE9A-related diseases. The method described involves administering an effective amount of the compound or composition to a subject in need of treatment.

Career Highlights

Kyu Yang Yi has worked with notable organizations such as the Korea Research Institute of Chemical Technology and Dongbu Hannong Chemical Co., Ltd. His experience in these institutions has allowed him to advance his research and contribute to the field of chemical technology.

Collaborations

Some of Yi's coworkers include Jee Hee Suh and Byung Ho Lee. Their collaboration has likely fostered an environment of innovation and shared expertise in their respective fields.

Conclusion

Kyu Yang Yi's contributions to the development of PDE9A inhibitory compounds highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for advancements in treating PDE9A-related diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com